Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) rose 2.7% on Friday . The company traded as high as $7.55 and last traded at $7.50, with a volume of 66,464 shares trading hands. The stock had previously closed at $7.30.

Separately, Needham & Company LLC initiated coverage on Aquinox Pharmaceuticals in a report on Thursday, May 12th. They set a “buy” rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.86.

The firm’s 50 day moving average price is $7.21 and its 200-day moving average price is $8.77. The firm’s market cap is $128.39 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Tuesday, May 10th. The company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. Equities analysts forecast that Aquinox Pharmaceuticals Inc. will post ($1.79) EPS for the current year.

Aquinox Pharmaceuticals, Inc, formerly Aquinox Pharmaceuticals (USA) Inc, is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc is a wholly owned subsidiary of the Company.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.